New KEYTRUDA ® (pembrolizumab) Data from KEYNOTE-006 and KEYNOTE-001 in Advanced Melanoma, Including Updated Survival Data, To Be Presented at 2016 ASCO Annual Meeting

< div class= " field field-type-text field-field-press-release-city field-fieldpressreleasecity " > < div class= " field-label " > Dateline City: < /div > < div class= " field-items " > < div class= " field-item odd " >
KENILWORTH, N.J. < /div > < /div > < /div > < div class= " field field-type-text field-field-press-release-subheadline field-fieldpressreleasesubheadline " > < div class= " field-items " > < div class= " field-item odd " > < p > Final Overall Survival Data from KEYNOTE-006 To Be Presented at ASCO; KEYTRUDA, the First Anti-PD-1 Monotherapy to Demonstrate  Overall Survival Compared to Ipilimumab, Shows Continued Benefit with Longer Follow-Up < /p > < p > KEYNOTE-001 Findings Show Continued Benefit in Response Rates, Duration of Response, and Include New Three-Year Overall Survival Data for KEYTRUDA < /p > < p > < /p > < /div > < /div > < /div > < p > KENILWORTH, N.J.--( < a target= " _blank " href= " http://www.businesswire.com " > BUSINESS WIRE < /a > )--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced final overall survival (OS) data from KEYNOTE-006 and
new findings from KEYNOTE-001, including updated response rates,
duration of response data and three-year OS data with KEYTRUDA < sup > ® < /sup >
(pembrolizumab), the company ’s anti-PD-1 therapy, in patients with
unresectable or metastatic melanoma. < /p > < div...

Source: Merck.com - Research and Development News - May 18, 2016 Category: Pharmaceuticals Tags: Research and Development News Corporate News Latest News Source Type: news